Nu Skin
Nu Skin's revenue fell 14.3% to $1.5 billion in fiscal 2025. Its operating margin was 4.4%, up from −8.8% a year earlier. Free cash flow was $46 million, down 34.4%. It paid out $32 million in dividends and buybacks, 69% of free cash flow. The diluted share count rose 1.3%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Nu Skin does
Nu Skin develops and sells skin care, personal care and wellness products in nearly 50 markets. Its two main product categories are beauty products, sold under brands such as Nu Skin and ageLOC, and wellness products, sold under brands such as Pharmanex. It also sells connected beauty and wellness devices that work with a mobile app.
It sells through direct selling: a sales force of independent distributors who promote and sell the products person to person, including on social and digital platforms. Revenue in 2025 was $1.5 billion, and about 26% of it came from the United States. Because most revenue is outside the United States, currency changes affect its results in dollars.
Nu Skin also runs Rhyz, an investment arm formed in 2018 that owns consumer, technology and manufacturing companies. Rhyz companies generated $223.6 million of 2025 revenue, or 15% of the reported total, excluding sales to its core Nu Skin business.
Its biggest risks, as it describes them
- Challenges to its network marketing system, or direct selling laws that restrict or ban it in some markets.
- Improper actions by its sales force, or social media platforms limiting the content its sales force posts.
- Its products and business opportunities failing to win acceptance from its sales force and customers.
- Intense competition and adverse publicity about its business or products.
- Its operations in Mainland China, which are subject to significant government regulation.
Income statement
From fiscal 2016 to 2025, earnings per share grew 2.5% a year and net income 1.3% a year, as buybacks cut the share count by 10%.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 355 | 278 | 268 | 198 | 240 |
| Debt incl. finance leases | 384 | 418 | 516 | 404 | 233 |
| Net debt (negative means net cash) | 29 | 139 | 248 | 206 | −7 |
| Net debt to EBITDA | 0.1x | 0.8x | 2.1x | — | −0.1x |
| Debt to equity | 0.4x | 0.5x | 0.6x | 0.6x | 0.3x |
| Interest coverage | 21.3x | 8.2x | 1.9x | −5.7x | 4.7x |
| Current ratio | 1.6x | 2.1x | 2.1x | 1.8x | 2.1x |
| Quick ratio | 0.9x | 1.1x | 1.3x | 1.2x | 1.4x |
Cash flow
Projections
Project Nu Skin's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Nu Skin says to expect
- Fourth quarter 2026: revenue and earnings per share
For the fourth quarter, we project revenue between $310 million and $340 million, with earnings per share in the range of $0.05 to $0.15 or $0.11 to $0.21 on an adjusted basis.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Nu Skin shares on the open market, and 3 insiders sold $99,547, $81,538 of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jun 2, 2026 | James M WinettDirector | Sold plan | 7,203 | $5.62 | $40,481 | Form 4 |
| Jun 1, 2026 | Edwina D WoodburyDirector | Sold plan | 7,203 | $5.70 | $41,057 | Form 4 |
| May 11, 2026 | Laura NathansonDirector | Sold | 2,676 | $6.73 | $18,009 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 5 of 9 | 4 of 9 | 7 of 9 |
| Rule of 40 | −8.5% | −8.0% | −11.2% |
| Altman Z'' | 5.78 | 5.02 | 7.36 |
| Accruals ratio | −6.1% | −15.8% | 5.6% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Fail | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Fail |
| Debt fell relative to assets | Fail | Pass | Pass |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Pass | Pass | Fail |
| Gross margin rose | Fail | Fail | Pass |
| Revenue rose relative to assets | Fail | Fail | Pass |
| F-score | 5 of 9 | 4 of 9 | 7 of 9 |
Compare
Put Nu Skin side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Nu Skin | FY25 | −14.3% | 4.4% | 3.1% | 6.5% | −0.1x | 7 | |
| e.l.f. Beauty | FY26 | 24.6% | 4.5% | 11.6% | 3.8% | 3.6x | 4 | Compare |
| USANA Health Sciences | FY25 | 8.3% | 4.0% | 0.9% | — | — | — | Compare |
| Nature's Sunshine Products | FY25 | 5.7% | 5.2% | 6.0% | 23.6% | −2.4x | 7 | Compare |
| Herbalife | FY25 | 0.9% | 9.6% | 5.0% | 36.6% | 2.7x | 6 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 2,208 | 2,279 | 2,679 | 2,420 | 2,582 | 2,696 | 2,226 | 1,969 | 1,732 | 1,485 |
| Revenue growth | −1.8% | 3.2% | 17.6% | −9.7% | 6.7% | 4.4% | −17.4% | −11.5% | −12.0% | −14.3% |
| Gross profit | 1,707 | 1,777 | 2,045 | 1,839 | 1,924 | 2,020 | 1,595 | 1,357 | 1,182 | 1,031 |
| Research and development | 24 | 22 | 23 | 30 | 23 | 27 | 23 | 23 | 13 | 11 |
| Operating income | 231 | 274 | 241 | 267 | 258 | 234 | 111 | 48 | −152 | 66 |
| Net income | 143 | 129 | 122 | 174 | 191 | 147 | 105 | 9 | −147 | 160 |
| Diluted EPS (US$) | 2.55 | 2.36 | 2.16 | 3.10 | 3.63 | 2.86 | 2.07 | 0.17 | −2.95 | 3.18 |
| Diluted shares (millions) | 56 | 55 | 56 | 56 | 53 | 51 | 50 | 50 | 50 | 50 |
| Cash flow | ||||||||||
| Cash from operations | 275 | 303 | 203 | 178 | 379 | 142 | 108 | 119 | 112 | 80 |
| Capital expenditure | 50 | 60 | 70 | 66 | 64 | 69 | 59 | 58 | 42 | 34 |
| Free cash flow | 225 | 242 | 132 | 112 | 315 | 73 | 49 | 60 | 70 | 46 |
| Dividends paid | 78 | 76 | 81 | 82 | 78 | 76 | 77 | 78 | 12 | 12 |
| Share buybacks | 247 | 72 | 70 | 1 | 144 | 80 | 70 | 13 | 0 | 20 |
| Acquisitions | 9 | 32 | 38 | 8 | 15 | 19 | 0 | 77 | 0 | 0 |
| Stock-based compensation | 9 | 19 | 27 | 10 | 24 | 23 | 12 | 16 | 15 | 24 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 368 | 438 | 398 | 344 | 424 | 355 | 278 | 268 | 198 | 240 |
| Debt incl. finance leases | 417 | 389 | 430 | 362 | 345 | 384 | 418 | 516 | 404 | 233 |
| Total assets | 1,474 | 1,590 | 1,694 | 1,769 | 1,957 | 1,906 | 1,821 | 1,809 | 1,469 | 1,405 |
| Total liabilities | 810 | 885 | 913 | 894 | 1,063 | 994 | 924 | 987 | 818 | 600 |
| Shareholders' equity | 664 | 705 | 782 | 875 | 894 | 913 | 897 | 822 | 652 | 805 |
| Margins and ratios | ||||||||||
| Gross margin | 77.3% | 78.0% | 76.3% | 76.0% | 74.5% | 75.0% | 71.7% | 68.9% | 68.2% | 69.5% |
| Operating margin | 10.5% | 12.0% | 9.0% | 11.1% | 10.0% | 8.7% | 5.0% | 2.5% | −8.8% | 4.4% |
| Net margin | 6.5% | 5.7% | 4.5% | 7.2% | 7.4% | 5.5% | 4.7% | 0.4% | −8.5% | 10.8% |
| Free cash flow margin | 10.2% | 10.6% | 4.9% | 4.6% | 12.2% | 2.7% | 2.2% | 3.0% | 4.0% | 3.1% |
| Rule of 40 (growth + FCF margin) | 8.4% | 13.9% | 22.5% | −5.0% | 18.9% | 7.1% | −15.2% | −8.5% | −8.0% | −11.2% |
| Return on capital | 20.9% | 20.1% | 18.2% | 21.3% | 22.5% | 16.9% | 11.2% | 2.3% | −12.4% | 6.5% |
| Return on equity | 19.2% | 18.9% | 16.4% | 20.9% | 21.6% | 16.3% | 11.6% | 1.0% | −19.9% | 22.0% |
| Return on assets | 9.6% | 8.4% | 7.4% | 10.0% | 10.3% | 7.6% | 5.6% | 0.5% | −8.9% | 11.2% |
| Net debt to EBITDA | 0.2x | −0.1x | 0.1x | 0.1x | −0.2x | 0.1x | 0.8x | 2.1x | — | −0.1x |